Furiex Pharmaceuticals Announces Agreement to Transfer Priligy(R) Product Rights
Currently Priligy is marketed by Janssen for on-demand treatment of premature ejaculation in 15 countries in Europe, Asia and Latin America, while it is approved for that indication in 43 countries worldwide. To ensure a smooth transition, Janssen will …
Read more on MarketWatch (press release)

Furiex Pharmaceuticals and Menarini Announce License Agreement for Priligy(R)
Currently, Priligy(R) is marketed for on-demand treatment of premature ejaculation in 15 countries in Europe, Asia and Latin America, while it is approved for that indication in 43 countries worldwide. Under the terms of the agreement, Furiex will be …
Read more on MarketWatch (press release)

In Spotlight: Healthcare Business Recap: Johnson & Johnson Drops This …
Johnson & Johnson's (NYSE:JNJ) subsidiary Alza Corporation, along with Janssen Pharmaceutica NV, will transfer global rights for development of their premature ejaculation treatment Priligy to drug developer Furiex Pharmaceuticals (NASDAQ:FURX).
Read more on The Mumbai Times